Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Xantho Biotechnology Co. Ltd. manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. At present, the portfolio contains 1 pending office action, which is being handled by MELLER, MICHAEL V. As the busiest examiner for the company, MELLER, MICHAEL V is responsible for 1 busiest examiner pending action. This indicates that the company's current prosecution workload is concentrated under the supervision of a single examiner.
The portfolio's structure is focused, with 1 distinct examiner and 1 distinct art unit involved in the current proceedings. This level of concentration suggests that the company's innovations are situated within a specific technical niche of the Biotechnology & Pharmaceuticals sector. For a patent practitioner, the presence of 1 distinct art unit simplifies the prosecution process by limiting the procedural rules to those of a single administrative division. Additionally, having 1 distinct examiner for the 1 pending office action allows for a more personalized and consistent interaction with the patent office. This streamlined profile reduces the need to manage multiple examiner styles or conflicting art unit requirements, allowing for a targeted and efficient patent acquisition strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MELLER, MICHAEL V | 1 | 47.3% | +28.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566672 | USE OF MANGOSTEEN FRUIT SHELL EXTRACT IN THE PREPARATION OF A MEDICAMENT FOR TREATING PSORIASIS | MELLER, MICHAEL V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566672 | USE OF MANGOSTEEN FRUIT SHELL EXTRACT IN THE PREPARATION OF A MEDICAMENT FOR TREATING PSORIASIS | MELLER, MICHAEL V | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18566672 | USE OF MANGOSTEEN FRUIT SHELL EXTRACT IN THE PREPARATION OF A MEDICAMENT FOR TREATING PSORIASIS | MELLER, MICHAEL V | 1655 | §102§103 | Non-Final OA | — | Pending | Dec 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXantho Biotechnology Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Michael V Meller has the most, with 1 of Xantho Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.